Literature DB >> 11651265

Placebo-controlled trials and the logic of clinical purpose.

Benjamin Freedman.   

Abstract

Keywords:  American Academy of Pediatrics; American College of Gastroenterology; Biomedical and Behavioral Research

Mesh：

Substances：

Year:  1990        PMID： 11651265

Source DB:  PubMed          Journal:  IRB        ISSN： 0193-7758


× No keyword cloud information.
  14 in total

1.  The standard of care debate: can research in developing countries be both ethical and responsive to those countries' health needs?

Authors:  David Wendler; Ezekiel J Emanuel; Reidar K Lie
Journal:  Am J Public Health       Date:  2004-06       Impact factor: 9.308

Review 2.  Placebo in the investigation of psychotropic drugs, especially antidepressants.

Authors:  Stanisław Puzyński
Journal:  Sci Eng Ethics       Date:  2004-01       Impact factor: 3.525

3.  Extending clinical equipoise to phase 1 trials involving patients: unresolved problems.

Authors:  James A Anderson; Jonathan Kimmelman
Journal:  Kennedy Inst Ethics J       Date:  2010-03

4.  Placebo tribulations.

Authors:  Glenn G Griener; Glenn G Grenier
Journal:  CMAJ       Date:  2002-09-03       Impact factor: 8.262

5.  Randomized controlled trials in environmental health research: ethical issues.

Authors:  David B Resnik
Journal:  J Environ Health       Date:  2008 Jan-Feb       Impact factor: 1.179

6.  Placebo orthodoxy and the double standard of care in multinational clinical research.

Authors:  Maya J Goldenberg
Journal:  Theor Med Bioeth       Date:  2015-02

Review 7.  What questions can a placebo answer?

Authors:  Spencer Phillips Hey; Charles Weijer
Journal:  Monash Bioeth Rev       Date:  2016-03

8.  Placebo Controlled Trials: Interests of Subjects versus Interests of Drug Regulators.

Authors:  Teguh Haryo Sasongko; Nor Hayati Othman; Nik Hazlina Nik Hussain; Yeong Yeh Lee; Sarimah Abdullah; Azlan Husin; Hans Van Rostenberghe
Journal:  Malays J Med Sci       Date:  2017-08-18

9.  Conflicts among multinational ethical and scientific standards for clinical trials of therapeutic interventions.

Authors:  Jacob M Kolman; Nelda P Wray; Carol M Ashton; Danielle M Wenner; Anna F Jarman; Baruch A Brody
Journal:  J Law Med Ethics       Date:  2012       Impact factor: 1.718

10.  Implications of FDA Approval of a First Disease-Modifying Therapy for a Neurodegenerative Disease on the Design of Subsequent Clinical Trials.

Authors:  Joshua D Grill; Jason Karlawish
Journal:  Neurology       Date:  2021-06-04       Impact factor: 11.800
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.